Synthesis and structure-activity relationships of constrained heterocyclic analogues of combretastatin A4

ChemMedChem

Volumn 6, Issue 9, 2011, Pages 1693-1705

  Arthuis, Martin ^a,b   Pontikis, Renée ^a,b   Chabot, Guy G ^c,d   Seguin, Johanne ^c,d   Quentin, Lionel ^c,d   Bourg, Stéphane ^e   Morin Allory, Luc ^e   Florent, Jean Claude ^a,b  

^a INSTITUT CURIE   (France)

^b CNRS   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

^d Centre National de la Recherche Scientifique   (France)

^e UNIVERSITÉ D'ORLÉANS   (France)

Author keywords

Antivascular agents; Combretastatin; Heterocyclic compounds; Palladium catalyzed reactions; Tubulin

Indexed keywords

1 BENZYL3 (3,4,5 TRIMETHOXYBENZYLIDENE)INDOLIN 2 ONE; 2 IODO 5 METHOXYPHENYLBUT 2 YNOATE; 2 IODOPHENYLBUT 2 YNOATE; 2,3,4 TRIMETHOXYBENZYLBUT 2 YNOATE; 3 (1 [3,4,5 TRIMETHOXYPHENYL] ETHYLIDENE) INDOLIN 2 ONE; 3 [1 (3 HYDROXY 4 METHOXYPHENYL) ETHYLIDENE] 5,6,7 TRIMETHOXY 1 [[2 (TRIMETHYLSILYL)ETHOXY] METHYL] INDOLINE 2 ONE; 3,4 (3,4,5 TRIMETHOXYPHENYL) BUT 3 EN 2 YLIDENE) BENZOFURAN 2 ONE; 3,4 (3,4,5 TRIMETHOXYPHENYL) BUT 3 EN 2 YLIDENE) INDOLIN 2 ONE; 6 IODO 2,3,4 TRIMETHOXYBENZOIC ACID; 6 IODO 2,3,4 TRIMETHOXYBENZYLBUT 2 YNOATE; 6 METHOXY 1 METHYL 3 [1 (3,4,5 TRIMETHOXYPHENYL) ETHYLIDENE] INDOLIN 2 ONE; 6 METHOXY 3 (1 (3,4,5 TRIMETHOXYPHENYL) ETHYLIDENE) INDOLIN 2 ONE; 6 METHOXY 3 [1 (3,4,5 TRIMETHOXYPHENYL) ETHYLIDENE] BENZOFUR; 6,7,8 TRIMETHOXY 4 [1 (4 METHOXYPHENYL) ETHYLIDENE] ISOCHROMAN 1 ONE; COMBRETASTATIN A4; COMBRETASTATIN A4 DERIVATIVE; HETEROCYCLIC COMPOUND; N (2 IODO 5 METHOXYPHENYL) BUT 2 YNAMIDE; N (2,3,4 TRIMETHOXYPHENYL)BUT 2 YNAMIDE; N (3 METHOXYPHENYL) N METHYLBUT 2 YNAMIDE; N [[2 (TRIMETHYLSILYL)ETHOXY] METHYL] N (2,3,4 TRIMETHOXYPHENYL) BUT 2 YNAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER INHIBITION; DRUG STRUCTURE; DRUG SYNTHESIS; ENDOTHELIUM CELL; MICROTUBULE ASSEMBLY; MOLECULAR DOCKING; MORPHOLOGY; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; CATALYSIS; CELL LINE, TUMOR; ENDOTHELIAL CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; MICE; PALLADIUM; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN;

EID: 80052086220     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201100154     Document Type: Article

References (108)

1. J. Folkman, N. Engl. J. Med. 1971, 285, 1182-1186.
2. J. Denekamp, Br. J. Radiol. 1993, 66, 181-196.
3. G. M. Tozer, C. Kanthou, B. C. Baguley, Nat. Rev. Cancer 2005, 5, 423-435.
4. C. Kanthou, G. M. Tozer, Int. J. Exp. Pathol. 2009, 90, 284-294.
5. D. W. Siemann, Cancer Treat. Rev. 2011, 37, 63-74, and references therein.
6. For reviews on VDAs, see:.
7. P. Hinnen, F. A. L. M. Eskens, Br. J. Cancer 2007, 96, 1159-1165.
8. J. W. Lippert III, Bioorg. Med. Chem. 2007, 15, 605-615.
9. S. X. Cai, Recent Pat. Anti-Cancer Drug Discovery 2007, 2, 79-101.
10. E. L. Schwartz, Clin. Cancer Res. 2009, 15, 2594-2601.
11. M. J. McKeage, B. C. Baguley, Cancer 2010, 116, 1859-1871.
12. M. A. Jordan, L. Wilson, Nat. Rev. Cancer 2004, 4, 253-265.
13. S. Honoré, E. Pasquier, D. Braguer, Cell. Mol. Life Sci. 2005, 62, 3039-3056.
14. For reviews on CA4, see:.
15. C. M. L. West, P. Price, Anti-Cancer Drugs 2004, 15, 179-187.
16. D. W. Siemann, D. J. Chaplin, P. A. Walicke, Expert Opin. Invest. Drugs 2009, 18, 189-197.
17. C. J. Mooney, G. Nagaiah, P. Fu, J. K. Wasman, M. M. Cooney, P. S. Savvides, J. A. Bokar, A. Dowlati, D. Wang, S. S. Agarwala, S. M. Flick, P. H. Hartman, J. D. Ortiz, P. N. Lavertu, S. C. Remick, Thyroid 2009, 19, 233-240.
18. G. J. Rustin, G. Shreeves, P. D. Nathan, A. Gaya, T. S. Ganesan, D. Wang, J. Boxall, L. Poupard, D. J. Chaplin, M. R. L. Stratford, J. Balkissoon, M. Zweifel, Br. J. Cancer 2010, 102, 1355-1360.
19. ClinicalTrials.gov, A service of the U.S. National Institutes of Health: (accessed June 6, 2011).
20. L. Vincent, P. Kermani, L. M. Young, J. Cheng, F. Zhang, K. Shido, G. Lam, H. Bompais-Vincent, Z. Zhu, D. J. Hicklin, P. Bohlen, D. J. Chaplin, C. May, S. Rafii, J. Clin. Invest. 2005, 115, 2992-3006.
21. C. Kanthou, G. M. Tozer, Blood 2002, 99, 2060-2069.
22. G. G. Dark, S. A. Hill, V. E. Prise, G. M. Tozer, G. R. Petitt, D. J. Chaplin, Cancer Res. 1997, 57, 1829-1834.
23. For reviews on CA4 analogues, see:.
24. N.-H. Nam, Curr. Med. Chem. 2003, 10, 1697-1722.
25. H. P. Hsieh, J. P. Liou, N. Mahindroo, Curr. Pharm. Des. 2005, 11, 1655-1677.
26. G. C. Tron, T. Pirali, G. Sorba, F. Pagliai, S. Busacca, A. A. Genazzani, J. Med. Chem. 2006, 49, 3033-3044.
27. T. Brown, H. Holt, Jr., M. Lee, Top Heterocycl. Chem. 2006, 2, 1-51.
28. R. Singh, H. Kaur, Synthesis 2009, 15, 2471-2491.
29. For recent reports on CA4 analogues with a stereochemically defined one-atom linker (1, 1-ethylene bridge), see:.
30. A. Hamze, A. Giraud, S. Messaoudi, O. Provot, J.-F. Peyrat, J. Bignon, J.-M. Liu, J. Wdzieczaek-Bakala, S. Thoret, J. Dubois, J.-D. Brion, M. Alami, ChemMedChem 2009, 4, 1912-1924.
31. R. Álvarez, C. Álvarez, F. Mollinedo, B. Sierra, M. Medarde, R. Peláez, Bioorg. Med. Chem. 2009, 17, 6422-6431.
32. For recent reports on heterocyclic CA4 derivatives, see:.
33. K. Bonezzi, G. Taraboletti, P. Borsotti, F. Bellina, R. Rossi, R. Giavazzi, J. Med. Chem. 2009, 52, 79066-7910.
34. R. Romagnoli, P. G. Baraldi, O. Cruz-Lopez, C. Lopez Cara, M. D. Carrion, A. Brancale, E. Hamel, L. Chen, R. Bortolozzi, G. Basso, G. Viola, J. Med. Chem. 2010, 53, 4248-4258.
35. R. Schobert, B. Biersack, A. Dietrich, K. Effenberger, S. Knauer, T. Mueller, J. Med. Chem. 2010, 53, 6595-6602.
36. B. Biersack, K. Effenberger, R. Schobert, M. Ocker, ChemMedChem 2010, 5, 420-427.
37. For recent reports on polycyclic derivatives derived from CA4, see:.
38. M.-J. Lai, C.-C. Kuo, T.-K. Yeh, H.-P. Hsieh, L.-T. Chen, W.-Y. Pan, K.-Y. Hsu, J.-Y. Chang, J.-P. Liou, ChemMedChem 2009, 4, 588-593.
39. A. Putey, F. Popowycz, Q.-T. Do, P. Bernard, S. K. Talapatra, F. Kozielski, C. M. Galmarini, B. Joseph, J. Med. Chem. 2009, 52, 5916-5925.
40. N. Ty, G. Dupeyre, G. G. Chabot, J. Seguin, L. Quentin, A. Chiaroni, F. Tillequin, D. Scherman, S. Michel, X. Cachet, Eur. J. Med. Chem. 2010, 45, 3726-3739.
41. V. Colombel, A. Joncour, S. Thoret, J. Dubois, J. Bignon, J. Wdzieczaek-Bakala, O. Baudouin, Tetrahedron Lett. 2010, 51, 3127-3129.
42. C. Bailly, C. Bal, P. Barbier, S. Combes, J.-P. Finet, M.-P. Hildebrand, V. Peyrot, N. Wattez, J. Med. Chem. 2003, 46, 6347-5444.
43. Some functionalized 2-arylbenzylidene derivatives displayed cytotoxic activity and act as tubulin polymerization inhibitors:.
44. N. J. Lawrence, D. Rennison, A. T. McGown, J. A. Hadfield, Bioorg. Med. Chem. Lett. 2003, 13, 3759-3763.
45. E. Rizzi, S. Dallavalle, L. Merlini, G. L. Beretta, G. Pratesi, F. Zunino, Bioorg. Med. Chem. Lett. 2005, 15, 4313-4316.
46. A. Andreani, S. Burnelli, M. Granaiola, A. Leoni, A. Locatelli, R. Morigi, M. Rambaldi, L. Varoli, M. W. Kunkel, J. Med. Chem. 2006, 49, 6922-6924.
47. B. Pandit, Y. Sun, P. Chen, D. L. Sackett, Z. Hu, W. Rich, C. Li, A. Lewis, K. Schaefer, P.- K. Li, Bioorg. Med. Chem. 2006, 14, 6492-6501.
48. A. Zuse, P. Schmidt, S. Baasner, K. J. Böhm, K. Müller, M. Gerlach, E. G. Günther, E. Unger, H. Prinz, J. Med. Chem. 2006, 49, 7816-7825.
49. J. Kaffy, R. Pontikis, J.-C. Florent, C. Monneret, Org. Biomol. Chem. 2005, 3, 2657-2660.
50. For pioneering works in this field, see:.
51. B. Burns, R. Grigg, V. Sridharan, P. Stevenson, S. Sukirthalingam, T. Worakun, Tetrahedron Lett. 1989, 30, 1135-1138.
52. C. H. Oh, Y. M. Lim, Tetrahedron Lett. 2003, 44, 267-270.
53. S. Couty, B. Liegault, C. Meyer, J. Cossy, Org. Lett. 2004, 6, 2511-2514.
54. W. S. Cheung, R. J. Patch, M. R. Player, J. Org. Chem. 2005, 70, 3741-3744.
55. R. Yanada, S. Obika, T. Inokuma, K. Yanada, M. Yamashita, S. Ohta, Y. Takemoto, J. Org. Chem. 2005, 70, 6972-6975.
56. A. Pinto, L. Neuville, P. Retailleau, J. Zhu, Org. Lett. 2006, 8, 4927-4930.
57. For a recent review on the synthesis of 3-alkenyloxindoles, see: A. Millemaggi, R. J. K. Taylor, Eur. J. Org. Chem. 2010, 4527-4547.
58. M. Arthuis, R. Pontikis, J.-C. Florent, Tetrahedron Lett. 2007, 48, 6397-6400.
59. 3N: S. Tang, P. Peng, P. Zhong, J.-H. Li, J. Org. Chem. 2008, 73, 5476-5480.
60. [24] O-methylation, hydrogenation).
61. C. L. Dwyer, C. W. Holzapfel, Tetrahedron 1998, 54, 7843-7848.
62. N. J. Lawrence, F. A. Ghani, L. A. Hepworth, J. A. Hadfield, A. T. McGown, R. G. Pritchard, Synthesis 1999, 1656-1660.
63. Removal of the SEM moiety was unsuccessful under the investigated conditions:.
64. J. M. Muchowski, D. R. Solas, J. Org. Chem. 1984, 49, 203-205.
65. G. Luo, L. Chen, G. Dubowchik, J. Org. Chem. 2006, 71, 5392-5395.
66. M. Arthuis, R. Pontikis, J.-C. Florent, J. Org. Chem. 2009, 74, 2234-2237.
67. M. Z. Cherkaoui, G. Scherowsky, New J. Chem. 1997, 21, 1203-1210.
68. C. Heusèle, D. Bonne, M.-F. Carlier, Eur. J. Biochem. 1987, 165, 613-620.
69. D. M. Barron, S. K. Chatterjee, R. Ravindra, R. Roof, E. Baloglu, D. G. Kingston, S. Bane, Anal. Biochem. 2003, 315, 49-56.
70. K. Grosios, S. E. Holwell, A. T. McGown, G. R. Pettit, M. C. Bibby, Br. J. Cancer 1999, 81, 1318-1327.
71. S. M. Galbraith, D. J. Chaplin, F. Lee, M. R. Stratford, R. J. Locke, B. Vojnovic, G. M. Tozer, Anticancer Res. 2001, 21, 93-102.
72. Compound 9g was synthesized by a Knoevenagel reaction.
73. 50=0.27μM). Thus, we suggest that substitution of the double bond with a methyl group, which prevents olefinic isomerization, does not perturb the interaction with tubulin.
74. [16d].
75. [17].
76. [21].
77. X. Ren, M. Dai, L.-P. Lin, P.-K. Li, J. Ding, Br. J. Pharmacol. 2009, 156, 1228-1238.
78. G. Micheletti, M. Poli, P. Borsotti, M. Martinelli, B. Imberti, G. Taraboletti, R. Giavazzi, Cancer Res. 2003, 63, 1534-1537.
79. A. Cirla, J. Mann, Nat. Prod. Rep. 2003, 20, 558-564.
80. M. B. Hadimani, J. Hua, M. D. Jonklaas, R. J. Kessler, Y. Sheng, A. Olivares, R. P. Tanpure, A. Weiser, J. Zhang, K. Edvardsen, R. R. Kane, K. G. Pinney, Bioorg. Med. Chem. Lett. 2003, 13, 1505-1508.
81. R. B. Ravelli, B. Gigant, P. A. Curmi, I. Jourdain, S. Lachkar, A. Sobel, M. Knossow, Nature 2004, 428, 198-202.
82. T. L. Nguyen, C. McGrath, A. R. Hermone, J. C. Burnett, D. W. Zaharevitz, B. W. Day, P. Wipf, E. Hamel, R. Gussio, J. Med. Chem. 2005, 48, 6107-6116.
83. G. Jones, P. Willett, R. C. Glen, J. Mol. Biol. 1995, 245, 43-53.
84. Y. Kong, J. Grembecka, M. C. Edler, E. Hamel, S. L. Mooberry, M. Sabat, J. Rieger, M. L. Brown, Chem. Biol. 2005, 12, 1007-1014.
85. C. Rappl, P. Barbier, V. Bourgarel-Rey, C. Grégoire, R. Gilli, M. Carre, S. Combes, J.-P. Finet, V. Peyrot, Biochemistry 2006, 45, 9210-9218.
86. S. Ducki, G. Mackenzie, B. Greedy, S. Armitage, J. Fournier DitChabert, E. Bennett, J. Nettles, J. P. Snyder, N. J. Lawrence, Bioorg. Med. Chem. 2009, 17, 7711-7722.
87. [45] as B-ring.
88. D. Simoni, F. P. Invidiata, M. Eleopra, P. Marchetti, R. Rondanin, R. Baruchello, G. Grisolia, A. Tripathi, G. E. Kellogg, D. Durrant, R. M. Lee, Bioorg. Med. Chem. 2009, 17, 512-522.
89. A. Tripathi, M. Fornabaio, G. E. Kellogg, J. T. Gupton, D. A. Gewirtz, W. A. Yeudall, N. E. Vega, S. L. Mooberry, Bioorg. Med. Chem. 2008, 16, 2235-2242.
90. R. Romagnoli, P. G. Baraldi, M. D. Carrion, C. Lopez Cara, O. Cruz-Lopez, D. Preti, M. Tolomeo, S. Grimaudo, A. DiCristina, N. Zonta, J. Balzarini, A. Brancale, T. Sarkar, E. Hamel, Bioorg. Med. Chem. 2008, 16, 5367-5376.
91. R. Romagnoli, P. G. Baraldi, M. D. Carrion, O. Cruz-Lopez, C. Lopez Cara, G. Basso, G. Viola, M. Khedr, J. Balzarini, S. Mahboobi, A. Sellmer, A. Brancale, E. Hamel, J. Med. Chem. 2009, 52, 5551-5555.
92. Y.-K. Chiang, C.-C. Kuo, Y.-S. Wu, C.-T. Chen, M. S. Coumar, J.-S. Wu, H.-P. Hsieh, C.-Y. Chang, H.-Y. Jseng, M.-H. Wu, J.-S. Leou, J.-S. Song, J.-Y. Chang, P.-C. Lyu, Y.-S. Chao, S.-Y. Wu, J. Med. Chem. 2009, 52, 4221-4233.
93. [47].
94. R. Yanada, S. Obika, Y. Kobayashi, T. Inokuma, M. Oyama, K. Yanada, Y. Takemoto, Adv. Synth. Catal. 2005, 347, 1632-1642.
95. C. Ma, X. Liu, X. Li, J. Flippen-Anderson, S. Yu, J. M. Cook, J. Org. Chem. 2001, 66, 4525-4542.
96. M. Tsukayama, H. Utsumi, A. Kunugi, H. Nozaki, Heterocycles 1997, 45, 1131-1142.
97. V. Rys, A. Couture, E. Deniau, P. Grandclaudon, Eur. J. Org. Chem. 2003, 1231-1237.
98. A. Maiti, P. V. N. Reddy, M. Cushman, M. Sturdy, S. Pegan, A. D. Mesecar, L. Marler, J. M. Pezzuto, J. Med. Chem. 2009, 52, 1873-1884.
99. M. M. Taafroot, Y. Landais, J.-P. Robin, D. Davoust, Tetrahedron Lett. 1986, 27, 1781-1784.
100. D. Bonne, C. Heusele, C. Simon, D. Pantaloni, J. Biol. Chem. 1985, 260, 2819-2825.
101. S. L. Bane, R. Ravindra, A. A. Zaydman in Microtubule Protocols (Ed.: J. Zhou), Humana Press, Totowa, 2007, pp.281-288.
102. C. J. Edgell, C. C. McDonald, J. B. Graham, Proc. Natl. Acad. Sci. USA 1983, 80, 3734-3737.
103. D. Bouis, G. A. Hospers, C. Meijer, G. Molena, N. H. Mulder, Angiogenesis 2001, 4, 91-102.
104. D. A. Scudiero, R. H. Shoemaker, K. D. Paull, A. Monks, S. Tierney, T. H. Nofziger, M. J. Currens, D. Seniff, M. R. Boyd, Cancer Res. 1988, 48, 4827-4833.
105. F. Zemani, D. Benisvy, I. Galy-Fauroux, A. Lokajczyk, S. Colliec-Jouault, G. Uzan, A. M. Fischer, C. Boisson-Vidal, Biochem. Pharmacol. 2005, 70, 1167-1175.
106. SybylX Suite, Tripos International, St. Louis MO (USA), 2009.
107. J. Sadowski, J. Gasteiger, Chem. Rev. 1993, 93, 2567-2581.
108. CORINA - Fast Generation of High-Quality 3D Molecular Models: (accessed June 6, 2011).